2020 APA实践指南:精神分裂症的治疗(第3版)

2020-09-01 美国精神病学会 Am J Psychiatry . 2020 Sep 1;177(9):868-872.

在2019年12月的会议上,美国精神病学家协会(APA)批准通过精神分裂症的治疗指南。该指南主要面向精神分裂症患者,目的是改善这些患者的护理治疗和治疗结局。

中文标题:

2020 APA实践指南:精神分裂症的治疗(第3版)

英文标题:

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

发布机构:

美国精神病学会

发布日期:

2020-09-01

简要介绍:

在2019年12月的会议上,美国精神病学家协会(APA)批准通过精神分裂症的治疗指南。该指南主要面向精神分裂症患者,目的是改善这些患者的护理治疗和治疗结局。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 APA实践指南:精神分裂症的治疗(第3版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=67d551c0019e8557, title=2020 APA实践指南:精神分裂症的治疗(第3版), enTitle=The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, guiderFrom=Am J Psychiatry . 2020 Sep 1;177(9):868-872., authorId=0, author=, summary=在2019年12月的会议上,美国精神病学家协会(APA)批准通过精神分裂症的治疗指南。该指南主要面向精神分裂症患者,目的是改善这些患者的护理治疗和治疗结局。, cover=https://img.medsci.cn/2020928/1601307827823_2020535.jpg, journalId=0, articlesId=null, associationId=33, associationName=美国精神病学会, associationIntro=美国精神病学协会,成立于1844年,是世界上最大的精神病届的组织。它是一个来自美国和世界各地的36000名精神科医生的医疗专业团体。其会员医生们一起工作,以确保人文关怀和有效的治疗所有精神障碍患者,包括智力发育障碍和物质使用障碍。APA是现代精神病学中的发言权和良知。APA成员的主要医疗专家是由精神科医生或在这个过程中逐渐成为精神科医生的。 APA有美国精神病学基金会(APF)、美国精神病学出版社(APP)、美国精神病学研究所的研究和教育(APIRE)3个部门。 美国精神病学会1991年开始建立指南,实践指南提供基于证据的精神疾病的评估和治疗建议,该学会指南专门为成人制定,关于儿童和青少年的精神疾病的治疗,指南,是由美国儿童和青少年精神病学制定。, copyright=0, guiderPublishedTime=Tue Sep 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>在2019年12月的会议上,美国精神病学家协会(APA)批准通过精神分裂症的治疗指南。该指南主要面向精神分裂症患者,目的是改善这些患者的护理治疗和治疗结局。</p> </div> </div> </div>, tagList=[TagDto(tagId=1344, tagName=精神分裂症)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1344, guiderKeyword=精神分裂症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8419, appHits=434, showAppHits=0, pcHits=2637, showPcHits=7985, likes=2, shares=23, comments=37, approvalStatus=1, publishedTime=Tue Sep 29 00:24:45 CST 2020, publishedTimeString=2020-09-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Sep 28 23:43:53 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:34:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 APA实践指南:精神分裂症的治疗(第3版).pdf)])
2020 APA实践指南:精神分裂症的治疗(第3版).pdf
下载请点击:
评论区 (29)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2118306, encodeId=4f32211830669, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230308/d7a771fed1c54c73abfcc1fd524f67e4/6c08389908624cc19f33816c4bb2a9ba.jpg, createdBy=12393687240, createdName=精神小伙昵称, createdTime=Wed Mar 08 18:56:10 CST 2023, time=2023-03-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099834, encodeId=549e2099834d2, content=學習, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:43:31 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079348, encodeId=79be10e9348b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46325544295, createdName=ms8000001575079939, createdTime=Sun Dec 12 23:48:00 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062784, encodeId=d7d61062e843a, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:03:02 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062783, encodeId=1a8d1062e832a, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:02:44 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2023-03-08 精神小伙昵称 来自安徽省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2118306, encodeId=4f32211830669, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230308/d7a771fed1c54c73abfcc1fd524f67e4/6c08389908624cc19f33816c4bb2a9ba.jpg, createdBy=12393687240, createdName=精神小伙昵称, createdTime=Wed Mar 08 18:56:10 CST 2023, time=2023-03-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099834, encodeId=549e2099834d2, content=學習, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:43:31 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079348, encodeId=79be10e9348b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46325544295, createdName=ms8000001575079939, createdTime=Sun Dec 12 23:48:00 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062784, encodeId=d7d61062e843a, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:03:02 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062783, encodeId=1a8d1062e832a, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:02:44 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2022-11-11 ozzy

    學習

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2118306, encodeId=4f32211830669, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230308/d7a771fed1c54c73abfcc1fd524f67e4/6c08389908624cc19f33816c4bb2a9ba.jpg, createdBy=12393687240, createdName=精神小伙昵称, createdTime=Wed Mar 08 18:56:10 CST 2023, time=2023-03-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099834, encodeId=549e2099834d2, content=學習, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:43:31 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079348, encodeId=79be10e9348b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46325544295, createdName=ms8000001575079939, createdTime=Sun Dec 12 23:48:00 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062784, encodeId=d7d61062e843a, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:03:02 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062783, encodeId=1a8d1062e832a, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:02:44 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-12-12 ms8000001575079939

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2118306, encodeId=4f32211830669, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230308/d7a771fed1c54c73abfcc1fd524f67e4/6c08389908624cc19f33816c4bb2a9ba.jpg, createdBy=12393687240, createdName=精神小伙昵称, createdTime=Wed Mar 08 18:56:10 CST 2023, time=2023-03-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099834, encodeId=549e2099834d2, content=學習, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:43:31 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079348, encodeId=79be10e9348b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46325544295, createdName=ms8000001575079939, createdTime=Sun Dec 12 23:48:00 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062784, encodeId=d7d61062e843a, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:03:02 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062783, encodeId=1a8d1062e832a, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:02:44 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-22 ms9000000309504242

    好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2118306, encodeId=4f32211830669, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230308/d7a771fed1c54c73abfcc1fd524f67e4/6c08389908624cc19f33816c4bb2a9ba.jpg, createdBy=12393687240, createdName=精神小伙昵称, createdTime=Wed Mar 08 18:56:10 CST 2023, time=2023-03-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2099834, encodeId=549e2099834d2, content=學習, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:43:31 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079348, encodeId=79be10e9348b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46325544295, createdName=ms8000001575079939, createdTime=Sun Dec 12 23:48:00 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062784, encodeId=d7d61062e843a, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:03:02 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062783, encodeId=1a8d1062e832a, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16bc5624889, createdName=ms9000000309504242, createdTime=Fri Oct 22 00:02:44 CST 2021, time=2021-10-22, status=1, ipAttribution=)]
    2021-10-22 ms9000000309504242

    好文章

    0

拓展阅读

WFSBP 精神分裂症的生物学治疗指南,第2部分:精神分裂症的长期治疗和抗精神病药物副作用的管理(2012年更新)

世界生物精神病学会联合会(WFSBP,World Federation of Societies of Biological Psychiatry) · 2012-12-06

2016 RANZCP临床实践指南:精神分裂症及其相关疾病的管理

澳大利亚与新西兰皇家精神科医师学会(RANZCP,Royal Australian and New Zealand college of Psychiatrists) · 2016-04-27

2019 BAP循证指南:精神分裂症的药物治疗(更新版)

英国精神药理协会(BAP,British Association for Psychopharmacology) · 2019-12-12

精神分裂症患者代谢综合征管理的中国专家共识

中华医学会精神病学分会 · 2020-01-30